Skip to main content

Table 1 Clinical characteristics for all patients and when stratified by lung disease category

From: Lung function and microbiota diversity in cystic fibrosis

  

Lung disease categorya

 

Severe

Moderate

Mild

All patients

< 40%

40–69%

≥ 70%

Number of patients

299

101

139

57

Sex (female:male)

137:160

39:62

66:73

32:25:00

Mean age (±SD)b

29.9 (± 10.2)

30.0 (± 10.8)

29.7 (± 10.1)

30.5 (± 9.5)

Mean %FEV1 (±SD)

49.5 (± 22.0)

25.5 (± 7.7)

53.2 (± 8.4)

82.8 (± 9.2)

CFTR Genotypec

 Homozygous F508del

153

46

75

32

 Heterozygous F508del

105

38

47

20

 Non-F508del

39

17

17

5

Clinical status (stable:exacerbation)d

86:211

43:58

38:101

5:52

CF related diabetes

119

54

50

15

Pancreatic insufficiency

250

91

111

48

Region

 Europe

161

58

73

30

 USA

136

43

66

27

CF Centre

 Bedford, NH, USA

17

5

9

3

 Belfast, Northern Ireland

27

12

13

2

 Boston, MA, USA

16

6

5

5

 Burlington, VT, USA

30

8

17

5

 Dublin, Ireland

1

0

1

0

 Lebanon, NH, USA

6

2

2

2

 London, UK

6

1

5

0

 New York, NY, USAe

5

2

1

0

 Newcastle, UK

26

16

8

2

 Portland, ME, USA

25

14

6

5

 Seattle, WA, USA

39

6

26

7

 Southampton, UK

94

29

39

26

 Warsaw, Poland

7

0

7

0

Antibioticsf

 Amikacin

12

6

6

0

 Azithromycin

64

34

22

8

 Aztreonam

59

24

27

8

 Ceftazidime

55

20

30

5

 Ciprofloxacin

17

3

12

2

 Colistin

59

32

21

6

 Co-trimoxazole

13

5

5

3

 Flucloxacillin

24

14

9

1

 Fosfomycin

10

5

5

0

 Meropenem

42

16

21

5

 Tobramycin

120

49

52

19

 Other antibiotics

113

39

58

14

  1. aPredicted %FEV1 used to define lung disease categories. bAge in years at time of sampling (minimum age 12 years, maximum 72 years), cCFTR genotype cystic fibrosis transmembrane conductance regulator genotype. Homozygous F508del, two copies of the F508del gene mutation. Heterozygous F508del, single copy of this mutation plus another mutation. dExacerbation is protocol-defined as receiving IV antibiotic treatment for worsening pulmonary status, as determined by the treatment team. eTwo patient samples from this centre were excluded from further analyses due to incomplete metadata. fDefined as having received a particular antibiotic within 2 weeks prior to sputum sampling. For brevity, only antibiotics administered to 10 or more of all patients are reported above. Other antibiotics included augmentin, cefepime, cefoxitin, ceftriaxone, cefuroxime, chloramphenicol, clindamycin, doripenem, doxycycline, imipenem, levofloxacin, linezolid, metronidazole, minocycline, moxifloxacin, rifampicin, tazocin, teicoplanin, temocillin, tigecycline and vancomycin